← All guides

Gantt Chart for Clinical Trial Management: From Protocol to Data Submission on One Timeline

How to manage a clinical trial project timeline with a Gantt chart — covering protocol development, IRB approval, site selection, enrollment, data collection, analysis, and regulatory submission.

Clinical trials are among the most complex, most regulated, and highest-stakes projects in existence. A single missed milestone can delay regulatory submission by months. A documentation gap during the audit phase can invalidate years of data. And unlike most projects, the participants are human beings whose safety depends on the trial being run correctly, not just on time.

Clinical trial project management requires meticulous planning, precise milestone tracking, and the ability to see how delays in one phase ripple across the entire study timeline. A Gantt chart for clinical trials provides that visibility — mapping every phase from protocol development through final submission on a single, shared timeline.

The Challenge of Clinical Trial Timelines

Clinical trials have timelines measured in years, not weeks. A Phase II trial might run 18–24 months from protocol finalization to final data lock. A Phase III pivotal trial might run 5–10 years. Within those long timelines, specific tasks have hard external deadlines — IRB submission windows, site initiation visit schedules, enrollment targets tied to statistical power calculations, and regulatory submission dates that can't slide.

The Gantt for a clinical trial isn't just a project management convenience. It's a compliance and safety document. It shows what was planned, when, and why. It provides the paper trail that auditors and regulatory agencies use to assess whether the study was conducted with appropriate rigor.

Phase 1: Protocol Development (Months 1–4)

The protocol is the master document that governs every aspect of how the trial is conducted. Nothing proceeds without it.

Key tasks:

  • Scientific rationale and literature review
  • Study design selection (randomized controlled trial, crossover, observational, adaptive)
  • Primary and secondary endpoint definition
  • Sample size calculation (based on statistical power analysis)
  • Eligibility criteria (inclusion/exclusion) development
  • Intervention and dosing schedule
  • Assessment schedule (visit schedule and data collection windows)
  • Statistical analysis plan (SAP) outline
  • Protocol drafting
  • Internal scientific review
  • Biostatistician review
  • Regulatory affairs review
  • Sponsor/PI approval
  • Protocol finalization

The Gantt dependency: the protocol must be finalized before IRB submission, site agreements, and CRF development can proceed. Rushing protocol development to accelerate the timeline creates errors that surface later — during conduct or submission — at far greater cost.

Phase 2: Regulatory and Ethics Review (Months 3–6)

Before any human subject can be enrolled, the trial must receive approval from the relevant ethics board (IRB in the US, IEC internationally) and, for drug trials, satisfy regulatory authority requirements.

Key tasks:

  • IRB application package preparation (protocol, IB or device description, consent forms, recruitment materials)
  • IRB submission
  • IRB review period (varies: expedited 2–4 weeks, full board 4–8 weeks)
  • Respond to IRB queries or conditions
  • IRB approval received
  • IND submission (for investigational drug trials) — submitted in parallel
  • FDA review period (30-day IND review)
  • Site-specific regulatory submissions (for multi-site trials)

The Gantt must reflect the reality that IRB review timelines are partially outside the trial team's control. Building buffer — and having a plan for responding to conditions quickly — keeps the IRB review from cascading into later phases.

For multi-site trials, each site may have its own IRB unless a central IRB arrangement is in place. Each site's IRB review timeline is a separate row on the Gantt, and site initiation is blocked until that site's approval is received.

Phase 3: Site Selection and Initiation (Months 4–8)

Multi-site trials require identifying, qualifying, and initiating research sites — a process that takes longer than sponsors typically plan for.

Key tasks:

  • Site feasibility questionnaire distribution
  • Site feasibility assessment and scoring
  • Site selection decision
  • Site contract and budget negotiation
  • Clinical Trial Agreement (CTA) execution
  • Site initiation visit (SIV) scheduling and execution
  • Site staff training (GCP, protocol, data systems)
  • IRB approval at each site
  • Investigational product shipment to site
  • Clinical trial management system (CTMS) and EDC access provisioning
  • Site readiness confirmation

Site contract negotiation is the phase most likely to slip. Each site negotiates its own contract, and contract review can take weeks at academic medical centers with active legal departments. The Gantt shows site activation as a milestone for each site, with contract execution as the dependency.

Phase 4: Study Startup Activities (Months 5–8, Parallel)

While sites are being initiated, several startup activities run in parallel.

Key tasks:

  • Case Report Form (CRF) design and build in Electronic Data Capture (EDC) system
  • EDC testing and user acceptance testing
  • Central laboratory selection and qualification
  • Laboratory manual preparation
  • Randomization system setup (IVRS/IWRS)
  • Data Safety Monitoring Board (DSMB) charter development and committee appointment
  • Safety reporting system configuration
  • Monitoring plan development
  • Risk-based monitoring strategy design
  • Training materials and investigator certification

EDC development is a commonly underestimated timeline. Building CRFs, configuring edit checks, running UAT, and training sites takes 6–10 weeks for a moderately complex study. On the Gantt, EDC development starts well before sites are ready, so the system is in place when the first site activates.

Phase 5: Enrollment and Data Collection (Months 8–30+)

Enrollment is typically the longest phase and the most variable. Enrollment rate predictions rarely match reality.

Key tasks:

  • Site activation (staggered as sites become ready)
  • Patient screening and eligibility assessment
  • Informed consent process
  • Randomization and treatment assignment
  • Study visit conduct per protocol schedule
  • Data entry into EDC
  • Site monitoring visits (routine on-site or remote per monitoring plan)
  • Protocol deviation identification and documentation
  • Safety event reporting (AEs, SAEs, protocol deviations)
  • DSMB meetings per charter
  • Enrollment tracking vs. target
  • Enrollment rate review and mitigation if below target

Enrollment tracking on the Gantt is done at the milestone level. Enrollment targets (e.g., "50% of target enrollment," "last patient in") are milestones on the Gantt with the statistical power implications noted. Missing enrollment milestones triggers a formal review of mitigation options: additional sites, protocol amendment to broaden eligibility, enhanced recruitment activities.

Phase 6: Data Management and Lock (Months 26–32)

As enrollment completes and the last protocol-required follow-up visits occur, attention shifts to data cleaning and lock.

Key tasks:

  • Last patient out (LPO) milestone
  • Outstanding query resolution
  • Data review and cleaning
  • Medical coding (MedDRA for adverse events, WHO drug dictionary for medications)
  • Database audit trail review
  • Protocol deviation reconciliation
  • External data integration (central lab, ECG, PK data)
  • Database lock preparation checklist
  • Database lock (formal, documented event)
  • Unblinding (for blinded studies)

Database lock is the most important milestone on the Gantt. Nothing can change in the data after lock. The analysis proceeds only after lock. Getting to database lock requires completing every open query, resolving every data discrepancy, and obtaining sign-off from the sponsor, CRO, and principal investigator.

Phase 7: Statistical Analysis (Months 30–34)

Analysis proceeds from the locked database according to the pre-specified statistical analysis plan.

Key tasks:

  • Analysis dataset creation and validation
  • Primary endpoint analysis
  • Secondary endpoint analysis
  • Safety analysis (adverse events, laboratory data)
  • Exploratory analyses
  • Statistical report
  • Medical review of statistical findings
  • Results interpretation and clinical review

The statistical analysis must proceed exactly as specified in the SAP. Any deviation from the pre-specified analysis requires documentation and justification. The Gantt shows analysis as a structured phase, not an informal "crunching numbers" step.

Phase 8: Regulatory Submission (Months 34–40)

For product approval trials, analysis results lead to regulatory submission — typically a New Drug Application (NDA), Biologics License Application (BLA), or Premarket Approval (PMA) for devices.

Key tasks:

  • Clinical study report (CSR) drafting
  • CSR medical and statistical review
  • CSR finalization
  • NDA/BLA assembly (clinical, nonclinical, CMC modules)
  • Regulatory agency submission
  • Agency review period (standard: 12 months; priority: 6 months)
  • Respond to agency questions (IR, complete response)
  • Label negotiations
  • Approval

Clinical study report writing alone typically takes 3–6 months for a pivotal trial. The Gantt allocates this time explicitly rather than treating it as a brief wrap-up activity.

Why Clinical Trials Need Gantt-Level Visibility

Clinical trial project managers use Gantt charts not just for scheduling but for risk management. When enrollment is running 20% below projections, the Gantt shows immediately how far the completion date slides. When a DSMB meeting requires a protocol amendment, the Gantt shows which downstream tasks are affected and by how much.

In an environment where a one-month delay can cost millions of dollars and — for patients waiting for a treatment — far more than money, the Gantt isn't administrative overhead. It's the operational infrastructure that makes complex, multi-year, multi-site trials manageable.